Stein EM. IDH2 inhibition in AML. Blood. 2023;141(2):124-125.

In the conflict-of-interest disclosure on page 125, the following disclosure for Eytan M. Stein should have been included: “E.M.S. served on advisory boards for and received consulting fees from Bristol Myers Squibb, Celgene, and Agios Pharmaceuticals. Also, Memorial Sloan Kettering Cancer Center received research funds from those 3 companies.”